Latest news with #TipRanks.com
Business Insider
5 hours ago
- Business
- Business Insider
Analysts Offer Insights on Technology Companies: PagerDuty (PD) and AvePoint (AVPT)
Companies in the Technology sector have received a lot of coverage today as analysts weigh in on PagerDuty (PD – Research Report) and AvePoint (AVPT – Research Report). Confident Investing Starts Here: PagerDuty (PD) Monness analyst Brian White maintained a Hold rating on PagerDuty on May 30. The company's shares closed last Friday at $14.26. According to White is a top 100 analyst with an average return of 17.7% and a 67.1% success rate. White covers the Technology sector, focusing on stocks such as Salesforce, Snowflake, and MongoDB. Currently, the analyst consensus on PagerDuty is a Hold with an average price target of $18.70, implying a 24.8% upside from current levels. In a report issued on May 21, TD Cowen also maintained a Hold rating on the stock with a $18.00 price target. AvePoint (AVPT) The company's shares closed last Friday at $18.65, close to its 52-week high of $19.90. According to Wood is a 5-star analyst with an average return of 15.0% and a 62.4% success rate. Wood covers the Technology sector, focusing on stocks such as Onestream, Inc. Class A, Klaviyo, Inc. Class A, and Rimini Street. Currently, the analyst consensus on AvePoint is a Strong Buy with an average price target of $21.00.
Business Insider
6 hours ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Bristol-Myers Squibb (BMY)
Analysts fell to the sidelines weighing in on Arvinas Holding Company (ARVN – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Arvinas Holding Company (ARVN) Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Arvinas Holding Company yesterday. The company's shares closed last Friday at $7.20. According to Biegler 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arvinas Holding Company with a $14.66 average price target, implying a 95.5% upside from current levels. In a report released yesterday, Leerink Partners also downgraded the stock to Hold with a $9.00 price target. Bristol-Myers Squibb (BMY) Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb on May 31. The company's shares closed last Friday at $48.28. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Eli Lilly & Co. The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $55.53 average price target, representing a 16.0% upside. In a report issued on May 16, BMO Capital also maintained a Hold rating on the stock with a $53.00 price target.
Business Insider
6 hours ago
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Gilead Sciences (GILD – Research Report). Confident Investing Starts Here: AbbVie (ABBV) In a report issued on May 31, Courtney Breen from Bernstein maintained a Hold rating on AbbVie. The company's shares closed last Friday at $186.11. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $212.13, implying a 14.7% upside from current levels. In a report issued on May 30, Berenberg Bank also maintained a Hold rating on the stock with a $170.00 price target. Gilead Sciences (GILD) In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences, with a price target of $125.00. The company's shares closed last Friday at $110.08. According to Biegler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $120.47, implying a 7.9% upside from current levels. In a report issued on May 21, Jefferies also maintained a Buy rating on the stock with a $130.00 price target.
Business Insider
8 hours ago
- Business
- Business Insider
Analysts Are Neutral on Top Consumer Cyclical Stocks: Ulta Beauty (ULTA), Costco (COST)
Analysts fell to the sidelines weighing in on Ulta Beauty (ULTA – Research Report) and Costco (COST – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Ulta Beauty (ULTA) Barclays analyst Adrienne Yih maintained a Hold rating on Ulta Beauty on May 30 and set a price target of $485.00. The company's shares closed last Friday at $471.46. According to Yih is a 4-star analyst with an average return of 6.3% and a 49.0% success rate. Yih covers the NA sector, focusing on stocks such as National Vision Holdings, Dick's Sporting Goods, and Canada Goose Holdings. Ulta Beauty has an analyst consensus of Moderate Buy, with a price target consensus of $463.17, representing a -1.1% downside. In a report issued on May 15, Piper Sandler also maintained a Hold rating on the stock with a $386.00 price target. Costco (COST) Barclays analyst Seth Sigman maintained a Hold rating on Costco on May 30 and set a price target of $1000.00. The company's shares closed last Friday at $1040.18, close to its 52-week high of $1078.23. According to Sigman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.3% and a 53.7% success rate. Sigman covers the NA sector, focusing on stocks such as Driven Brands Holdings, Floor & Decor Holdings, and Advance Auto Parts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Costco with a $1081.82 average price target, representing a 7.9% upside. In a report issued on May 29, Wells Fargo also maintained a Hold rating on the stock with a $1000.00 price target.
Business Insider
2 days ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on scPharmaceuticals (SCPH – Research Report), 10x Genomics (TXG – Research Report) and Kura Oncology (KURA – Research Report). Confident Investing Starts Here: scPharmaceuticals (SCPH) Leerink Partners analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals on May 14 and set a price target of $11.00. The company's shares closed last Friday at $3.22. According to Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 28.3% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Lexicon Pharmaceuticals, and Enanta Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $15.60 average price target, implying a 432.4% upside from current levels. In a report issued on May 12, Craig-Hallum also maintained a Buy rating on the stock. 10x Genomics (TXG) In a report issued on May 14, Puneet Souda from Leerink Partners maintained a Hold rating on 10x Genomics. The company's shares closed last Friday at $9.39, close to its 52-week low of $8.92. According to Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 29.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $12.56, a 36.2% upside from current levels. In a report issued on May 9, TD Cowen also maintained a Hold rating on the stock with a $11.00 price target. Kura Oncology (KURA) In a report issued on May 14, Jonathan Chang from Leerink Partners reiterated a Buy rating on Kura Oncology, with a price target of $23.00. The company's shares closed last Friday at $6.02. According to Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.0% and a 28.1% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics. Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $22.60, a 279.2% upside from current levels. In a report issued on May 1, TD Cowen also maintained a Buy rating on the stock.
